NanoViricides Inc. (NNVC)

[BonelessCat]

My claim is that EbolaCide, when it works will be effective against all types. It is a treatment and not a vaccine. You are thinking in terms of immunity following treatment, as am I, but you you are also thinking in terms of vaccine efficacy which is not treatment efficacy. We will only know how effective it is as a future preventive after treating and curing Ebola infections.

That immunity against all types MAY BE incomplete does not negate that EbolaCide SHOULD BE effective against ALL TYPES of Ebola as a treatment. Again, it is not a vaccine, but it in theory should have the effect of a vaccine in stimulating the immune system to produce sufficient antibodies to be effective later. The antibodies produced against a wild virus type should be of broader spectrum than those produced by either attenuated or dead virus vaccines as well as nucleic acid or toxoid based vaccines.

There is one more use for EbolaCide that I believe is not an option for other treatments, and that is its use prophylactically. If it proves effective in the wild and in use against human Ebola infections, then it can be administered as a preventive to people in the community around the outbreak cluster or to the communities on the leading edge of the outbreak areas.

One more thing, "However, if the live virus causes the immune response, the antibodies produced can be broader spectrum" is not made up. Wild viruses have all their active attachment points attenuated and dead viruses have those points reduced. A challenge of the Ebola virus in particular is that attenuated and dead viruses don't operate in the same way. You should already know about the drawbacks of neucleic acid and toxoid based vaccines, especially regarding Ebola and its many strategies for defeating immune response.